Claims
- 1. A method for at least in part inhibiting anti-parallel coiled coil formation of a coronavirus spike protein, said method comprising:
decreasing the contact between heptad repeat regions of the coronavirus spike protein.
- 2. The method according to claim 1 wherein said decrease is provided by a peptide and/or a functional fragment and/or an equivalent thereof.
- 3. The method according to claim 2 wherein said decrease is provided by a peptide comprising a heptad repeat region of a corona viral spike protein and/or a functional fragment and/or an equivalent thereof.
- 4. The method according to any of claims 1-3, wherein said heptad repeat region comprises an amino acid sequence of SARS HR2 according to FIG. 9, and/or a functional fragment and/or an equivalent thereof.
- 5. The method according to claim 1, wherein said decrease is provided by an antibody and/or a functional fragment and/or an equivalent thereof.
- 6. The method according to any of claims 1-5, wherein said coronavirus is a group 1 coronavirus.
- 7. The method according to claim 6, wherein said coronavirus is a feline coronavirus.
- 8. The method according to claim 7, wherein said feline coronavirus is feline infectious peritonitis (FIP) virus.
- 9. The method according to claim 6, wherein said coronavirus comprises a human corona virus.
- 10. The method according to any of claims 1-5, wherein said coronavirus comprises a group 2 coronavirus.
- 11. The method according to claim 10, wherein said coronavirus comprises a mouse hepatitis virus (MHV).
- 12. The method according to any of claims 1-5, wherein said coronavirus causes Severe Acute Respiratory Syndrome (SARS).
- 13. A method for inhibiting coronavirus spike protein mediated cell to cell fusion, said method comprising:
decreasing the contact between said spike protein's heptad repeat regions.
- 14. A method of selecting a binding compound to a heptad repeat region of a coronavirus spike protein, said method comprising:
contacting in vitro at least one heptad region of a coronavirus spike protein with a collection of compounds and measuring the formation of an anti-parallel coiled coil in said protein.
- 15. A binding compound selected by the method according to claim 14.
- 16. An antibody or a functional fragment and/or equivalent thereof, said antibody or functional fragment and/or equivalent thereof capable of decreasing the contact between heptad repeat regions of a coronavirus spike protein.
- 17. A pharmaceutical composition comprising:
the binding compound of claim 15, and/or an antibody or functional fragment and/or equivalent thereof capable of decreasing the contact between heptad repeat regions of a coronavirus spike protein, and a suitable diluent and/or carrier.
- 18. A method of treating coronavirus infections, said method comprising:
providing to a subject the pharmaceutical: composition of claim 17.
- 19. A diagnostic kit for detecting coronavirus infection in a sample taken from a subject, said diagnostic kit comprising:
the binding compound of claim 15 or an antibody or functional fragment and/or equivalent thereof capable of decreasing the contact between heptad repeat regions of a coronavirus spike protein, and means for detecting binding of said compound or antibody to said coronavirus.
- 20. A diagnostic kit for detecting coronavirus antibodies in a sample taken from a subject, said diagnostic kit comprising:
the binding compound of claim 15, and means for detecting binding of said compound to said antibodies.
- 21. A method of attenuating a coronavirus, said method comprising:
decreasing the contact between heptad repeat regions of the spike protein of said coronavirus.
- 22. An attenuated coronavirus characterized in that the contact between heptad repeat regions of the spike protein of said coronavirus is decreased.
Priority Claims (1)
Number |
Date |
Country |
Kind |
01201861.0 |
May 2001 |
EP |
|
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation in part of PCT International Patent Application No. PCT/NL/02/00318, filed on May 17, 2002, designating the United States of America, and published, in English, as PCT International Publication No. WO 02/092827 A2 on Nov. 11, 2002, the contents of the entirety of which is incorporated by this reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/NL02/00318 |
May 2002 |
US |
Child |
10414256 |
Apr 2003 |
US |